Form 4: Director Gillian Cannon Sells Xenon Pharmaceuticals Shares

Xenon Pharmaceuticals Director Gillian Cannon sold 1,190 common shares to cover tax obligations related to RSU vesting.

Summary

• Director Gillian Cannon sold 1,190 common shares of Xenon Pharmaceuticals (XENE).
• The transaction occurred on June 5, 2026, at a price of $53.14 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2025.
• Following the transaction, the director retains 1,455 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and specifically designated for tax obligations.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating the transaction was not based on non-public information.

Negatives

• Reduction in direct equity ownership by a company director.

Risks

• None identified; this is a routine tax-related divestment.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs.

Industry Context

StockSavvy.ai notes that routine insider selling to cover tax obligations upon the vesting of equity awards is a standard corporate practice and generally does not signal a change in management sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for directors and executives to manage equity divestments while avoiding potential insider trading concerns.

Stakeholder Impact

• Minimal impact on shareholders as the sale was a routine tax-related transaction.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Insider Trading, Form 4, Director Sale, Biotech